Cargando…
P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
Autores principales: | Shah, Harsh, Vardell, Victoria, Zacholski, Erin, Fegley, Amanda, Fedak, Kalub, Sundaram, Suchitra, Rajeeve, Sridevi, Goyal, Gaurav, Hatic, Haris, Torka, Pallawi, Ba Aqeel, Sheeba, Borogovac, Azra, Macdougall, Kira, Kothari, Shalin, Kress, Anna, Modi, Dipenkumar, Travers, Elizabeth, Chilakamarri, Nitin, Brem, Elizabeth, Stephens, Deborah M., Hu, Boyu, Fitzgerlad, Lindsey, Wagner, Charlotte, Ermann, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621536/ http://dx.doi.org/10.1097/01.HS9.0000890976.21005.88 |
Ejemplares similares
-
P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022) -
P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022) -
P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022) -
P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022) -
P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)